In its first two rounds, the company aspired to demonstrate that its technology would work at least as well as the existing method of testing for DNA, proteins, and small molecules.
FORBES: MIT Spinoff, T2 Biosystems, Hopes To Slash Deadly Hospital Infection Deaths